Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Investing.com - PTC Therapeutics reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
PTC Therapeutics announced earnings per share of $-1.53 on revenue of $217.10. Analysts polled by Investing.com EPS of $-1.31 on revenue of $178.9M.
PTC Therapeutics 's are down 18% and is trading at $38.00 , still down 20.06% from its 52 week high of $55.58 set on Tuesday, September 20, 2022.
PTC Therapeutics shares lost 14.47% to trade at $38.00 in after-hours trade the report.
PTC Therapeutics follows other major Healthcare sector earnings this month
PTC Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.9B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar